Phase 3 N=332 Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Cure Rate Against Strongyloides Stercoralis — 94.8; 99.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants
Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology
Phase 2 N=700 Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Trichuriasis · Hookworm Infections
Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants
Phase 2 N=12 Desensitising Celiac Disease Patients With the Human Hookworm
Celiac Disease
Primary: Duodenal Villus Height:Crypt Depth — 2.73; 2.73 Ratio — p=0.693
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
Phase 1 N=36 Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Crohn's Disease
Primary: Incidence of Adverse Events — 7; 4; 1; 7 events
Phase 2 N=39 Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
Hookworm Infections
Primary: Detectable Hookworm Infection — 0; 0; 0; 0 Participants
Phase 3 N=214 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections
Necator Americanus Infection
Primary: Cure Rate — 16.3; 28.3; 18.8 percentage of participants
Phase 3 N=224 Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
Phase 3 N=536 Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Egg Reduction Rate Against T. Trichiura — 96.8; 99.0; 86.2; 94.2 Percent change
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 2 N=260 Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)
Phase 4 N=186 Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children
Hookworm
Primary: Cure Rate (CR) of Mebendazole Against Hookworm — 13; 97.9 percentage of participants cured
N/A N=17,108 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Lymphatic Filariasis · Soil Transmitted Helminth Infections
Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants
Phase 2 N=370 S. Japonicum and Pregnancy Outcomes
Schistosomiasis
Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988
Early Phase 1 N=12 Ivermectin and Human Immunity
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0
Phase 2 N=250 Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Crohn's Disease
Primary: Evaluate the Effects of TSO on the Induction of Response in Crohn's Disease, as Measured Primarily by Crohn's Disease Activity Index (CDAI) — 55; 58 Participants
Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
Phase 2 N=8 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Loiasis
Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028
Phase 2 N=354 Praziquantel in Children Under Age 4
Schistosomiasis · Schistosomiasis Mansoni · Schistosoma Japonicum Infection
Primary: Treatment Efficacy — 96; 98; 96; 98 percentage change
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Phase 1 N=36 Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers
Helminthic Infection
Primary: Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3 — 3; 3; 1 Participants